Lv1
56 积分 2023-03-23 加入
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
21天前
已完结
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
21天前
已完结
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
25天前
已关闭
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
28天前
已完结
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials
28天前
已完结
Phase 3 Trials of Inhaled Treprostinil for Idiopathic Pulmonary Fibrosis
1个月前
已关闭
Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11
1个月前
已完结
Idiopathic Pulmonary Fibrosis
1个月前
已完结
2023 Chinese national clinical practice guideline on diagnosis and management of ulcerative colitis
1个月前
已完结
Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
4个月前
已完结
皖公网安备34019202002308
